Wegovy recommended to HSE for some patients despite cost

The NCPE found that Wegovy offers value for money for certain patients in Ireland’s public healthcare system. It recommended that the HSE consider making the medicine available to public patients with high body mass indexes, provided they meet specified clinical criteria.

The recommendation does not cover everyone seeking weight-loss treatment. The assessment focuses on people with a BMI of 27kg to 30kg who also have a weight-related condition, and people with a BMI of 30kg or more, who are considered obese. Wegovy would be used alongside diet and increased physical activity.

The recommendation is not yet a final approval. The HSE Drugs Group will examine the assessment and make a recommendation to HSE Senior Leadership. That process may take several months, while the estimated five-year cost for all eligible groups is around €4.4 billion.

Wegovy is a medicine made by Novo Nordisk for weight management. The article describes it as intended for people who are overweight or obese. It is not presented as a stand-alone solution. Its use is combined with a reduced-calorie diet and increased physical activity.

The assessment calculates its public cost using a weekly dose of 2.4 milligrams. At that dose, the estimated price is €2,918 for each eligible patient per year, or €243 per month. The medicine is aimed at people whose weight meets the proposed BMI thresholds, including some patients with weight-related conditions.

Its intended role is therefore part of a broader weight-management plan. The article does not explain how Wegovy works inside the body or describe expected weight-loss amounts. It focuses instead on its indication, dosing assumption, price, and possible access through the public system.

The proposed criteria target public patients whose body mass index indicates overweight or obesity. One group would have a BMI from 27kg to 30kg and at least one weight-related condition. A second group would have a BMI of 30kg or more and would therefore be deemed obese.

For example, a patient in the 27kg-to-30kg BMI range would need both the relevant BMI and a weight-related condition. A patient with a BMI of 30kg or above would fall into the obesity group described in the assessment. Wegovy would also be used with a reduced-calorie diet and increased physical activity.

These criteria come from the NCPE’s cost assessment and describe the population used for its estimates. They do not mean that every patient in those groups can receive the medicine immediately. The HSE Drugs Group must first consider the assessment, followed by a recommendation to HSE Senior Leadership and a final decision.

The NCPE’s estimate puts Wegovy’s annual cost at €2,918 for each eligible patient. That works out at €243 per month. The calculation assumes a weekly dose of 2.4 milligrams, giving the HSE a standard basis for estimating public expenditure.

The largest figure is the potential impact across all eligible population groups. If the medicine were made publicly available to the full population covered by the proposed criteria, the five-year budget cost would be around €4.4 billion. This is the total scale of spending, not the price charged to one patient.

The high budget impact matters because public funding must cover the treatment for many potential patients. Even so, the NCPE judged Wegovy cost-effective and value for money, and said the HSE should consider making it available under clinical criteria. The Drugs Group must still review the assessment before any final decision.

The NCPE assessment is an important recommendation, but it does not itself put Wegovy on the HSE public system. Its conclusion is that the HSE should consider supplying the medicine to eligible patients under clinical criteria. The assessment now moves into the HSE’s decision-making process.

First, the HSE Drugs Group will consider the NCPE’s findings. The group will then make a recommendation to HSE Senior Leadership. Senior Leadership is responsible for the final decision described in the article. Until that process is completed, public access is not confirmed.

The article gives no guaranteed launch date. It says the process may take several months. The eventual decision will therefore determine whether eligible public patients can receive Wegovy through the HSE, and under what arrangements. The potential cost will be a major consideration because the full eligible population could cost around €4.4 billion over five years.

The main difference identified in the article is price. Wegovy was assessed at €2,918 per eligible patient each year. Mounjaro was assessed at €5,526 to €6,214 annually in December 2025 and was judged not cost-effective at that price.

Professor Michael Barry said Wegovy has a lower cost than Mounjaro. A lower price can improve the value-for-money assessment when the medicines are being considered for similar weight-management use. The article does not provide a detailed comparison of their clinical benefits or effectiveness, so the price difference is the clearest stated explanation.

Mounjaro’s manufacturer later made a new pricing offer to the State. That could have reduced its public cost to about €2-€3 billion a year, but the HSE Drugs Group still made no recommendation on it that week. Wegovy’s assessment is therefore positive, but its final public funding decision remains pending.

For a publicly funded healthcare system, a medicine is cost-effective when its expected health benefits are judged to justify its cost. This usually involves comparing the treatment’s price and benefits with available alternatives and the system’s limited budget. It is a value judgment about spending, not simply a search for the cheapest medicine.

In this case, the NCPE judged Wegovy cost-effective and value for money at an estimated €2,918 per eligible patient each year. That assessment uses the proposed patient groups and a weekly 2.4-milligram dose. The article does not provide the detailed health-benefit calculations behind the conclusion.

Cost-effectiveness can coexist with a large total bill. The NCPE still estimated around €4.4 billion over five years if the full eligible population received Wegovy. That high budget impact is why the HSE must consider affordability and implementation before Senior Leadership makes a final decision.